Description

 

Thymosin alpha-1 (Ta1) is a pivotal molecule in the realm of biologically active peptides.

 

Produced by the thymus gland, specifically from the thymosin fraction 5, this peptide has demonstrated a significant impact on the immune system.

Its immunomodulatory properties, which balance and enhance immune responses, make it a promising candidate in medical research.

 

Ta1’s ability to modulate immune responses has garnered increasing interest in the scientific community, especially for its potential application in treating a range of immune-related diseases.

These diseases, which often compromise the body’s ability to defend against infections and other threats, could greatly benefit from Ta1’s therapeutic properties:

Hepatitis C: Known for its immunomodulatory properties, Ta1 might improve treatment outcomes for hepatitis C.

However, clinical studies have not yet definitively confirmed its efficacy.

Hepatitis B: The combination of lamivudine and Ta1 has shown significant improvements in treating hepatitis B compared to lamivudine alone, particularly in normalizing alanine aminotransferase and reducing viral replication.

COVID-19: A pilot study suggested that Ta1 might assist in managing hospitalized COVID-19 patients, especially those with hypoxemia and lymphocytopenia.

Immunodeficiency Disorders: Ta1 has shown potential in modulating the immune response against viral infections like HIV-1 and HTLV-1.

Vaccine Adjuvant: Ta1 might enhance the immune response generated by the influenza vaccine, especially in elderly and immunocompromised populations.

Bacterial and Fungal Infections: Ta1 has been explored for its benefits in treating various infectious conditions, such as Pseudomonas infections, and has shown promising immunomodulatory effects.

Other Applications: Ta1 is also being investigated for treating chronic fatigue syndrome, psoriatic arthritis, and for its potential anti-aging and neuroprotective properties.

 

Key Benefits of THYMOSIN ALPHA-1:

 

• T-Cell Development: Promotes the maturation and functionality of T cells, essential for the immune response.

 

• Hepatitis Therapy: Has shown potential in treating hepatitis B and C, improving treatment response and reducing liver inflammation.

 

• COVID-19 Treatment: In pilot studies, it has shown potential in assisting the management of hospitalized COVID-19 patients.

 

• Sleep Regulation: Can influence the sleep cycle by increasing melatonin levels, a hormone that regulates sleep.

 

• DNA Repair: Has shown potential in protecting and repairing DNA from damage.

 

• Cancer Research: Preclinical studies suggest it might play a role in cancer prevention.

 

• Vaccine Adjuvant: Enhances the immune response generated by vaccines, improving their efficacy.

 

Dosage of THYMOSIN ALPHA-1:

 

Regarding intake, the effective dosage of THYMOSIN ALPHA-1 is 500mcg once daily via subcutaneous injection for 20 days, to be repeated twice a year.

 

Need more info bout this product?

 

Disclaimer: This PRODUCT IS INTENDED AS A RESEARCH CHEMICAL ONLY. This designation allows the use of research chemicals strictly for in vitro testing and laboratory experimentation only. All product information available on this website is for educational purposes only. Bodily introduction of any kind into humans or animals is strictly forbidden by law. This product should only be handled by licensed, qualified professionals. This product is not a drug, food, or cosmetic and may not be misbranded, misused or mislabled as a drug, food or cosmetic.
ALKEMYA BV accepts no liability in case of misuse of this product.